The Problem: Every Year, Over 60,000 People Go Blind from Diabetic Retinopathy
How LumineticsCore Works
1
Using a fundus camera, the trained operator captures two images per eye
2
The images are submitted to LumineticsCore
👁 background graphics
👁 background graphics
3
LumineticsCore analyzes images for signs of diabetic retinopathy, providing results in less than a minute
Results
More than mild diabetic retinopathy (mtmDR) NOT detected: Retest in 12 months
Results
More than mild diabetic retinopathy (mtmDR) detected: Refer to an eye care professional
LumineticsCore – How It Works | Play Video
Our Approach to AI Driven Diagnostics
AI the Right Way
LumineticsCore is modeled to look for and make decisions based on the same clinical disease detectors that eye care specialists would use.
- Diagnostic AI built on an ethical foundation
- Diagnostic results at the point-of-care
- Infinitely scalable
High Performance in a
Real-World Clinical Setting
Safety
LumineticsCore was validated against patient outcomes using a surrogate outcome standard to keep patient safety the main priority.
Effectiveness
In our pivotal clinical trial, LumineticsCore avoided 91% of unnecessary specialty visits by providing a diagnostic result at the point-of-care that showed patients as negative for more than mild diabetic retinopathy.
Accessibility
LumineticsCore has been trained and validated to mitigate bias and ensure the system works equally well for all people, regardless of sex, race, or ethnicity. For more information, read the LumineticsCore pivotal trial.
Who is LumineticsCore for?
Digital Diagnostics is impacting patient care across the globe.
Front-Line Care Providers
LumineticsCore is for medical professionals who want to leverage AI innovation to provide patients with a rigorously validated and ethically designed system for diabetic retinopathy diagnosis. LumineticsCore results are provided at the point-of-care, allowing providers to present actionable next steps during the initial patient encounter. LumineticsCore also provides the opportunity for improved quality measure performance for the eye exam for diabetes and can be reimbursed with CPT code 92229.
Ophthalmologists & Optometrists
LumineticsCore is for eye care providers to help address a known gap in care and improve patient access to the eye exam for diabetes. LumineticsCore results can help increase actionable referrals by identifying patients with diabetic retinopathy who are not already under the care of an eye care provider. This can help increase access for the patients who are most likely to need timely vision-saving interventions.
Payor Community
LumineticsCore is for payors to improve healthcare efficiency and access to care for enrollees while supporting the Patient Centered Medical Home (PCMH).
- Cost savings over the life-time of care
- Prevent blindness through early disease detection
- 100% compliance for diabetic retinopathy exams saves > $5B/year
Patients
LumineticsCore is for adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy and are not currently under the care of an eye care specialist. LumineticsCore is installed at point-of-care locations to increase patient access and convenience.
Indications for Use
LumineticsCore is intended for use by health care providers to automatically detect more than mild diabetic retinopathy (mtmDR) in adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy. LumineticsCore is indicated for use with the Topcon NW400.
Tarzana Treatment Centers
"This AI technology has improved satisfaction for both patients and the clinical team by providing clinicians with real-time data to manage diabetes more effectively. Support staff feel a sense of pride and accomplishment when explaining the technology to patients. The integration of LumineticsCore with EPIC has made our busy clinics into a convenient one stop shop. What we want in Medicine!"
Michael P. Soles, MD, Medical Champion Tarzana Treatment Centers
Johns Creek Primary Care
“LumineticsCore really is cutting-edge technology that helps me market to patients, prevent vision loss from diabetes, and improve my quality scores”
Lee Herman, MD, FACP Johns Creek Primary Care
Cahaba Medical Care
“An immediate point-of-care result is great to close the communications loop with the patient. The more you can get done when the patient is at the visit is better.”
John B. Waits, MD, FAAFP, Chief Executive Officer Cahaba Medical Care
Tarzana Treatment Centers
“Patients are empowered when they see how their retina looks and what a worse outcome prognosis could be. In this case, the patient was so motivated to not lose his sight that he dropped his HbA1c within three months. We are now discussing decreasing daily insulin dosages.”
Tarzana Treatment Centers, Provider Overseeing Diabetes Care
Tarzana Treatment Center
“It’s been a godsend for us.”
Christian Espinoza, Director of Clinic Operations Tarzana Treatment Centers
Zufall Health
“The identification of organ damage also provides crucial feedback for the patient and medical team regarding the need for intensifying or improving overall diabetes care.”
Douglas Bishop, MD Family Medicine Provider at Zufall Health Center
University Medical Center
“It’s a better and more efficient system that allows us to do more exams.”
LumineticsCore Operator at UMC
OSF Healthcare
“Nearly one-quarter of all patients with diabetes who received the [LumineticsCore] exam tested positive for diabetic retinopathy. The AI can see the early changes of diabetic retinopathy that we may not be able to see with our own eyes.There’s nothing as good as prevention.”
Mark Meeker, DO, VP of Community Medicine at OSF HealthCare
LumineticsCore FAQ
What is LumineticsCore?
LumineticsCore detects more than mild diabetic retinopathy, which is ETDRS level 35 or higher at the point-of-care to provide the patient with a diagnostic report without a physician evaluation. After completing a rigorous prospective, preregistered clinical trial at primary care sites across the country, LumineticsCore became the first FDA De Novo-cleared AI diagnostic system to make a diagnosis without physician input. LumineticsCore is deployed in point-of-care offices across the country.
What are the indications for LumineticsCore?
LumineticsCore is intended for use by health care providers to automatically detect more than mild diabetic retinopathy, which is ETDRS level 35 or higher in adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy.
Warnings
- LumineticsCore does not replace a full eye exam, but it will find diabetic retinopathy that needs to be examined by an eye doctor. Patients who have blurry vision or other symptoms of vision loss should see an eye doctor right away.
- While LumineticsCore is reliable, it is not perfect. It is possible that LumineticsCore is unable to detect disease that is present, or possibly give a false positive diagnosis.
To review the LumineticsCore Indications for Use click here.
How does LumineticsCore work?
Using a fundus camera, an operator captures high-quality images of the patients’ eyes. The images are then submitted to LumineticsCore where they are analyzed for signs of diabetic retinopathy. A diagnostic result is provided during the patient encounter with follow up instructions for the patient based on the diagnosis. If actionable disease is detected, the patient is referred to an eye care professional, which has been shown to increase the chances of the patient following through with the referral appointment. If no actionable disease is detected the patient is advised to get retested in 12 months based on AAO annual exam guidelines.
Who is LumineticsCore for?
Patients
LumineticsCore is for adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy and are not currently under the care of an eye care specialist. LumineticsCore is installed at point-of-care locations to increase patient access and convenience.
Providers
LumineticsCore is for medical professionals who want to provide patients with rigorously validated and ethically designed diagnostic results at the point-of-care, allowing for more comprehensive diabetes care and improved performance with eye exams for people with diabetes quality measures.
Payors
LumineticsCore is for payors to help improve healthcare efficiency and access to care for enrollees while supporting the Patient Centered Medical Home (PCMH).
Eye Care Providers
LumineticsCore is for eye care providers to help address disparities and improve access to care as part of the eye exam for diabetes delivery model. LumineticsCore results can lead to more actionable referrals, identifying disease in patients not already under the care of an eye care provider, who are most likely to need timely vision saving interventions.
What is autonomous AI?
Autonomous AI is a technology that can make clinical and diagnostic decisions that impact patient care without the need for physician involvement.